Publique en esta revista
Información de la revista
Vol. 49. Núm. S1.
Consenso SEPAR-ALAT sobre terapia inhalada
Páginas 2-14 (Enero 2013)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 49. Núm. S1.
Consenso SEPAR-ALAT sobre terapia inhalada
Páginas 2-14 (Enero 2013)
DOI: 10.1016/S0300-2896(13)70068-1
Acceso a texto completo
Consenso SEPAR-ALAT sobre terapia inhalada
SEPAR-ALAT Consensus for Inhaled Therapies
Visitas
31374
Este artículo ha recibido
31374
Visitas
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Giner, L.V. Basualdo, P. Casan, C. Hernández, V. Macian, I. Martínez, et al.
Normativa SEPAR para la utilización de fármacos inhalados. Recomendaciones SEPAR N.º 22.
Doyma, (1997),
[2.]
V. Giraud, N. Roche.
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability.
Eur Respir J, 19 (2002), pp. 246-251
[3.]
A.S. Melani, M. Bonavia, V. Cilenti, C. Cinti, M. Lodi, P. Martucci, et al.
Inhaler mishandling remains common in real life and is associated with reduced disease control.
Respir Med, 105 (2011), pp. 930-938
[4.]
V. Plaza, J. Sanchis, P. Roura, J. Molina, M. Calle, S. Quirce, et al.
Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain.
J Aerosol Med Pulm Drug Deliv, 25 (2012), pp. 16-22
[5.]
D. Price, S. Bosnic-Anticevich, A. Briggs, H. Chrystyn, C. Rand, G. Scheuch, The Inhaler Error Steering Committee, et al.
Inhaler competence in asthma: common errors, barriers to use and recommended solutions.
Respir Med, 107 (2013), pp. 37-46
[6.]
J. Sanchis, C. Corrigan, M.L. Levy, J.L. Viejo, ADMIT Group.
Inhaler devices–from theory to practice.
Respir Med, 107 (2013), pp. 495-502
[7.]
B.L. Laube, H.M. Janssens, F.H. De Jongh, S.G. Devadason, R. Dhand, P. Diot, European Respiratory Society; International Society for Aerosols in Medicine, et al.
What the pulmonary specialist should know about the new inhalation therapies.
Eur Respir J, 37 (2011), pp. 1308-1331
[8.]
V. Plaza, M. Calle, J. Molina, S. Quirce, J. Sanchis, J.L. Viejo, et al.
Validación externa de las recomendaciones del Consenso multidisciplinar sobre Terapia Inhalada.
Arch Bronconeumol, 48 (2012), pp. 189-196
[9.]
Inhalation aerosols. Physical and biological basis for therapy, 2nd,
[10.]
S.P. Newman.
Aerosol deposition considerations in inhalation therapy.
Chest, 882 (1985), pp. 152S-160S
[11.]
A. Fernández Tena, P. Casan Clarà.
Depósito pulmonar de partículas inhaladas.
Arch Bronconeumol, 48 (2012), pp. 240-246
[12.]
M. Lippmann, D.B. Yeates, R.E. Albert.
Deposition, retention, and clearance of inhaled particles.
Br J Ind Med, 37 (1980), pp. 337-362
[13.]
M.A. Dolovich.
Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung.
Respir Care, 45 (2000), pp. 597-608
[14.]
L. De Rochefort, L. Vial, R. Fodil, X. Maitre, B. Louis, D. Isabey, et al.
In vitro validation of computational fluid dynamic simulation in human proximal airways with hyperpolarized 3He magnetic resonance phase-contrast velocimetry.
J Appl Physiol, 102 (2007), pp. 2012-2023
[15.]
D.B. Gail, C.J. Lenfant.
Cells of the lung: biology and clinical implications.
Am Rev Respir Dis, 127 (1983), pp. 366-387
[16.]
P. Satir, M.A. Sleigh.
The physiology of cilia and mucociliary interactions.
Annu Rev Physiol, 52 (1990), pp. 137-155
[17.]
L. Hendeles, G.L. Colice, R.J. Meyer.
Withdrawal of albuterol inhalers containing chlorofluorocarbon propellants.
N Engl J Med, 356 (2007), pp. 1344-1351
[18.]
M.B. Dolovich, R. Dhand.
Aerosol drug delivery: developments in device design and clinical use.
Lancet, 377 (2011), pp. 1032-1045
[19.]
N. Scichilone, M. Spatafora, S. Battaglia, R. Arrigo, A. Benfante, V. Bellia.
Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations.
J Asthma Allergy, 6 (2013), pp. 11-21
[20.]
B.J. Gabrio, S.W. Stein, D.J. Velasquez.
A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers.
Int J Pharm, 186 (1999), pp. 3-12
[21.]
S.P. Newman, A.W. Weisz, N. Talaee, S.W. Clarke.
Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique.
Thorax, 46 (1991), pp. 712-716
[22.]
B. Zierenberg, J. Eicher, S. Dunne, B. Freund.
Boehringer Ingelheim nebulizer BINEB®: a new approach to inhalation therapy.
Proceedings of Respiratory Drug Delivery V, pp. 187-193
[23.]
B. Zierenberg.
Optimizing the in vitro performance of Respimat.
J Aerosol Med, 12 (1999), pp. S19-S24
[24.]
F. Lavorini, G.A. Fontana.
Targeting drugs to the airways: The role of spacer devices.
Expert Opin Drug Deliv, 6 (2009), pp. 91-102
[25.]
J. Boe, J.H. Dennis, B.R. O’Driscoll, T.T. Bauer, M. Carone, B. Dautzenberg, European Respiratory Society Task Force on the use of nebulizers, et al.
European Respiratory Society Guidelines on the use of nebulizers.
Eur Respir J, 18 (2001), pp. 228-242
[26.]
J.C. Virchow, G.K. Crompton, R. Dal Negro, S. Pedersen, A. Magnan, J. Seidenberg, et al.
Importance of inhaler devices in the management of airway disease.
Respir Med, 102 (2008), pp. 10-19
[27.]
W. Wilkes, J. Fink, R. Dhand.
Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler.
J Aerosol Med, 14 (2001), pp. 351-360
[28.]
J. Panicker, G.R. Sethi, V. Sehgal.
Comparative efficiency of commercial and improvised spacer device in acute bronchial asthma.
Indian Pediatr, 38 (2001), pp. 340-348
[29.]
H.J. Zar, E.G. Weinberg, H.J. Binns, F. Gallie, M.D. Mann.
Lung deposition of aerosol–a comparison of different spacers.
Arch Dis Child, 82 (2000), pp. 495-498
[30.]
J. Giner, M. Torrejon, A. Ramos, P. Casan, C. Granel, V. Plaza, et al.
Preferencias de los pacientes en la elección de dispositivos de inhalación en polvo.
Arch Bronconeumol, 40 (2004), pp. 106-109
[31.]
A.R.H.A. Clark.
The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers–implications for in vitro testing.
J Aerosol Med, 6 (1993), pp. 99-110
[32.]
H. Chrystyn.
Effects of device design on patient compliance: comparing the same drug in different devices.
Respiratory Drug Delivery Europe 2009, pp. 105-116
[33.]
O.S. Usmani, M.F. Biddiscombe, P.J. Barnes.
Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size.
Am J Respir Crit Care Med, 172 (2005), pp. 1497-1504
[34.]
H. Chrystyn, D. Price.
What you need to know about inhalers and how to use them.
Prescriber, 20 (2009), pp. 47-52
[35.]
R. Sechaud, M. Sudershan, S. Perry, H. Hara, A. Drollmann, R. Karan, et al.
Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in man.
ERS Annual Congress,
[36.]
P. Colthorpe, T. Voshaar, T. Kieckbusch, E. Cuoghi, J. Jauernig.
Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long acting muscarinic antagonist glycopyrronium.
Journal of Drug Assessment. 2013 Journal of Drug Assessment, 2 (2013), pp. 11-16
[37.]
G.M. Pover, C.G. Langdon, S.R. Jones, C. Fidler.
Evaluation of a breath operated powder inhaler.
J Int Med Res, 16 (1988), pp. 201-203
[38.]
H. Chrystyn.
The Diskus: a review of its position among dry powder inhaler devices.
Int J Clin Pract, 61 (2007), pp. 1022-1036
[39.]
K. Wetterlin.
Turbuhaler: a new powder inhaler for administration of drugs to the airways.
Pharm Res, 5 (1988), pp. 506-508
[40.]
H. Magnussen, H. Watz, I. Zimmermann, S. Macht, R. Greguletz, M. Falques, et al.
Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD.
Respir Med, 103 (2009), pp. 1832-1837
[41.]
S.P. Newman, D.J. Sutton, R. Segarra, R. Lamarca, G. De Miquel.
Lung deposition of aclidinium bromide from Genuair, a multidose dry powder inhaler.
Respiration, 78 (2009), pp. 322-328
[42.]
H. Chrystyn.
Closer to an ‘ideal inhaler’ with the Easyhaler: an innovative dry powder inhaler.
Clin Drug Investig, 26 (2006), pp. 175-183
[43.]
T.T. Yang, S. Li, B. Wyka, D. Kenyon.
Drug delivery performance of the mometasone furoate dry powder inhaler.
J Aerosol Med, 14 (2001), pp. 487-494
[44.]
F. Mariotti, F. Sergio, D. Acerbi, T. Meyer, C. Herpich.
Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients.
ERS Annual Congress,
[45.]
D. Singh, G. Lucci, D. Acerbi, F. Sergio, I. Montagna, S. Vezzoli, et al.
Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®.
ERS Annual Congress,
[46.]
P.G. Linnane, T. Voshaar, M. Spinola, A. Campanini, D. Lock, M. Scuri, et al.
Usability evaluation of NEXThaler® versus Diskus® and Turbuhaler®.
ERS Annual Congress,
[47.]
J. Lotvall, E.D. Bateman, E.R. Bleecker, W.W. Busse, A. Woodcock, R. Follows, et al.
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids.
Eur Respir J, 40 (2012), pp. 570-579
[48.]
D.R. Hess.
Aerosol delivery devices in the treatment of asthma.
Respir Care, 53 (2008), pp. 699-723
[49.]
S. Newman, A. Gee-Turner.
The Omron MicroAir vibrating mesh nebulizer, a 21st century approach to inhalation.
J Appl Ther Res, 5 (2005), pp. 29-33
[50.]
J.C. Waldrep, A. Berlinski, R. Dhand.
Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer.
J Aerosol Med, 20 (2007), pp. 310-319
[51.]
R. Dhand.
Aerosol delivery during mechanical ventilation: from basic techniques to new devices.
J Aerosol Med Pulm Drug Deliv, 21 (2008), pp. 45-60
[52.]
H.M. Janssens, H.A. Tiddens.
Aerosol therapy: the special needs of young children.
Paediatr Respir Rev, 7 (2006), pp. S83-S85
[53.]
F. Burgos.
¿Son compatibles la calidad y el uso extensivo de la espirometría?.
Arch Bronconeumol, 42 (2006), pp. 311-313
[54.]
M.B. Dolovich, R.C. Ahrens, D.R. Hess, P. Anderson, R. Dhand, J.L. Rau, et al.
Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology.
Chest, 127 (2005), pp. 335-371
[55.]
V. Plaza, J. Sanchis.
Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. CESEA Group.
Respiration, 65 (1998), pp. 195-198
[56.]
V. Plaza, J. Sanchis, P. Roura, J. Molina, M. Calle, S. Quirce, et al.
Physicians’ knowledge of inhaler devices and inhalation techniques remains poor in Spain.
J Aerosol Med Pulm Drug Deliv, 25 (2012), pp. 16-22
[57.]
J. Van der Palen, J.J. Klein, C.L. Van Herwaarden, G.A. Zielhuis, E.R. Seydel.
Multiple inhalers confuse asthma patients.
Eur Respir J, 14 (1999), pp. 1034-1037
[58.]
S.W. Stoloff, D.A. Stempel, J. Meyer, R.H. Stanford, J.R. Carranza Rosenzweig.
Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies.
J Allergy Clin Immunol, 113 (2004), pp. 245-251
[59.]
J.B. Fink, B.K. Rubin.
Problems with inhaler use: a call for improved clinician and patient education.
Respir Care, 50 (2005), pp. 1360-1374
[60.]
J.L. Rau.
Practical problems with aerosol therapy in COPD.
Respir Care, 51 (2006), pp. 158-172
[61.]
Gema educadores. Manual del educador en asma. Madrid: Editorial Luzán 5; 2010. Disponible en: http://www.gemasma.com
[62.]
A. López Viña.
Actitudes para fomentar el cumplimiento terapéutico en el asma.
Arch Bronconeumol, 41 (2005), pp. 334-340
[63.]
M.E. Hyland.
Types of noncompliance.
Eur Respir Rev, 8 (1998), pp. 255-259
[64.]
S.P. Newman, F. Morén, D. Pavia, F. Little, S.W. Clarke.
Deposition of pressurized suspension aerosols inhaled through extension devices.
Am Rev Respir Dis, 124 (1981), pp. 317-320
[65.]
W. De Backer, A. Devolder, G. Poli, D. Acerbi, R. Monno, C. Herpich, et al.
Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.
J Aerosol Med Pulm Drug Deliv, 23 (2010), pp. 137-148
[66.]
S.P. Newman, G.R. Pitcairn, D.A. Adkin, M.T. Vidgren, M. Silvasti.
Comparison of beclomethasone dipropionate delivery by easyhaler dry powder inhaler and pMDI plus large volume spacer.
J Aerosol Med, 14 (2001), pp. 217-225
[67.]
J. Richards, P. Hirst, G. Pitcairn, S. Mahashabde, W. Abramowitz, A. Nolting, et al.
Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants.
J Aerosol Med, 14 (2001), pp. 197-208
[68.]
S.P. Newman, J. Brown, K.P. Steed, S.J. Reader, H. Kladders.
Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices.
Chest, 113 (1998), pp. 957-963
[69.]
H.M. Janssens, A. Krijgsman, T.F. Verbraak, W.C. Hop, J.C. De Jongste, H.A. Tiddens.
Determining factors of aerosol deposition for four pMDI-spacer combinations in an infant upper airway model.
J Aerosol Med, 17 (2004), pp. 51-61
[70.]
C. Leach.
Effect of formulation parameters on hydrofluoroalkane-beclomethasone dipropionate drug deposition in humans.
J Allergy Clin Immunol, 104 (1999), pp. S250-S252
[71.]
C.L. Leach, P.J. Davidson, R.J. Boudreau.
Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.
Eur Respir J, 12 (1998), pp. 1346-1353
[72.]
S. Häussermann, D. Acerbi, P. Brand, C. Herpich, G. Poli, K. Sommerer, et al.
Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients.
J Aerosol Med, 20 (2007), pp. 331-341
[73.]
R. Nave.
Determination of lungdeposition following inhalation of ciclesonide using different bioanalytical procedures.
Bioanalysis, 2 (2010), pp. 807-814
[74.]
S. Newman, A. Salmon, R. Nave, A. Drollmann.
High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma.
Respir Med, 100 (2006), pp. 375-384
[75.]
S.P. Newman, M.T. Newhouse.
Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects.
J Aerosol Med, 9 (1996), pp. 55-57
[76.]
P. Brand, B. Hederer, G. Austen, H. Dewberry, T. Meyer.
Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
Int J Chron Obstruct Pulmon Dis, 3 (2008), pp. 763-770
[77.]
G. Pitcairn, S. Reader, D. Pavia, S. Newman.
Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
J Aerosol Med, 18 (2005), pp. 264-272
[78.]
L. Agertoft, S. Pedersen.
Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.
Am J Respir Crit Care Med, 168 (2003), pp. 779-782
[79.]
T. Meyer, P. Brand, H. Ehlich, R. Köbrich, G. Meyer, F. Riedinger, et al.
Deposition of Foradil P in human lungs: comparison of in vitro and in vivo data.
J Aerosol Med, 17 (2004), pp. 43-49
[80.]
R. Delvadia, M. Hindle, P.W. Longest, P.R. Byron.
In Vitro Tests for Aerosol Deposition II: IVIVCs for Different Dry Powder Inhalers in Normal Adults.
J Aerosol Med Pulm Drug Deliv, (2012),
[81.]
P.H. Hirst, R.E. Bacon, G.R. Pitcairn, M. Silvasti, S.P. Newman.
A comparison of the lung deposition of budesonide from Easyhaler. Turbuhaler and pMDI plus spacer in asthmatic patients.
Respir Med, 95 (2001), pp. 720-727
[82.]
M. Vidgren, A. Kärkkäinen, P. Karjalainen, P. Paronen, J. Nuutinen.
Effect of powder inhaler design on drug deposition in the respiratory tract.
Int J Pharm, 42 (1988), pp. 211-216
[83.]
S.P. Newman, F. Morén, E. Trofast, N. Talaee, S.W. Clarke.
Deposition and clinical efficacy of terbutalinesulphate from Turbuhaler, a new multi-dose powder inhaler.
Eur Respir J, 2 (1989), pp. 247-252
[84.]
L. Thorsson, S. Edsbäcker, T.B. Conradson.
Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI.
Eur Respir J, 7 (1994), pp. 1839-1844
[85.]
L. Borgström, E. Bondesson, F. Morén, E. Trofast, S.P. Newman.
Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects.
Eur Respir J, 7 (1994), pp. 69-73
[86.]
Y. Zhang, K. Gilbertson, W.H. Finlay.
In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
J Aerosol Med, 20 (2007), pp. 227-235
[87.]
R. Berger, W.E. Berger.
Particle size and small airway effects of mometasone furoate delivered by dry powder inhaler.
Allergy Asthma Proc, 34 (2013), pp. 52-58
[88.]
Becker A, Lemanske R, Pedersen S, Sly PL, Soto-Quiroz M, Wong GW, et al. Global Strategy for Asthma Management and Prevention in Children 5 Years and Younger. 2009. Disponible en: http://www.ginasthma.org
[89.]
M.L. García García.
Inhaladores para el lactante y el niño.
pp. 107-114
Copyright © 2013. Sociedad Española de Neumología y Cirugía Torácica
Idiomas
Archivos de Bronconeumología

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.